Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Nipent pentostatin: Phase II; marketed to treat hairy cell leukemia

In an Italian Phase II trial in 30 patients receiving

Read the full 108 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE